{"transactions":[{"id":687433,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":false,"shares":2074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests and is exercisable as to approximately 16% of the underlying shares on August 1, 2019, approximately 74% of the underlying shares in 28 substantially equal monthly installments beginning on September 1, 2019, and approximately 10% of the underlying shares in 12 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":70.04,"expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":2074},"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687432,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":false,"shares":3348,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests and is exercisable as to approximately 13% of the underlying shares on August 11, 2019, and the remaining of the underlying shares in 40 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":68.74,"expiration_date":"2029-02-11","underlying":"Common Stock","underlying_shares":3348},"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687431,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":false,"shares":16179,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests and is exercisable as to approximately 14% of the underlying shares on August 5, 2022, approximately 64% of the underlying shares in 28 substantially equal monthly installments beginning on September 5, 2022, and approximately 22% of the underlying shares in 12 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":52.84,"expiration_date":"2032-05-05","underlying":"Common Stock","underlying_shares":16179},"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687430,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":false,"shares":7171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests and is exercisable as to approximately 14% of the underlying shares on April 1, 2021, approximately 73% of the underlying shares in 32 substantially equal monthly installments on May 5, 2021, and approximately 13% of the underlying shares in 10 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":57.22,"expiration_date":"2030-10-01","underlying":"Common Stock","underlying_shares":7171},"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687429,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":false,"shares":2869,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The original grant of 4,039 stock options vests and is exercisable as to approximately 15% of the underlying shares on August 13, 2020, approximately 70% of the underlying shares in 28 substantially equal monthly installments beginning on September 13, 2020, and approximately 15% of the underlying shares in 12 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":55.75,"expiration_date":"2030-02-13","underlying":"Common Stock","underlying_shares":2869},"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687428,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"sale","planned":true,"acquired":false,"shares":31641,"price":292.065,"value":9241228.665,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.0098 to $292.0846. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":27696,"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687427,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":true,"shares":3348,"price":68.74,"value":230141.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."}],"balance_after":59337,"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687426,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":true,"shares":7171,"price":57.22,"value":410324.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."}],"balance_after":55989,"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687425,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":true,"shares":2869,"price":55.75,"value":159946.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."}],"balance_after":48818,"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687424,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":true,"shares":2074,"price":70.04,"value":145262.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."}],"balance_after":45949,"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687423,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":true,"shares":16179,"price":52.84,"value":854898.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."}],"balance_after":43875,"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":716388,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:09.000Z","date":"2026-06-30","kind":"other","planned":false,"acquired":true,"shares":17,"price":160.7095,"value":2732.0615,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":27696,"source":{"system":"sec-edgar","filing":"0002001011-26-000107","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000107/edgardoc.xml","form_type":"4"}},{"id":760782,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-05-28T23:43:04.000Z","date":"2026-05-27","kind":"exercise","planned":false,"acquired":false,"shares":764,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from December 5, 2022, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after December 5, 2022 and the remaining stock options vesting in 42 equal monthly installments thereafter."}],"balance_after":17407,"derivative":{"exercise_price":63.62,"expiration_date":"2032-12-13","underlying":"Common Stock","underlying_shares":764},"source":{"system":"sec-edgar","filing":"0002001011-26-000071","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000071/edgardoc.xml","form_type":"4"}},{"id":760781,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-05-28T23:43:04.000Z","date":"2026-05-27","kind":"exercise","planned":false,"acquired":false,"shares":972,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to approximately 55% of the underlying shares in 12 substantially equal monthly installments beginning on January 5, 2025, and approximately 45% of the underlying shares in two substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":52.84,"expiration_date":"2032-05-05","underlying":"Common Stock","underlying_shares":972},"source":{"system":"sec-edgar","filing":"0002001011-26-000071","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000071/edgardoc.xml","form_type":"4"}},{"id":760780,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-28T23:43:04.000Z","date":"2026-05-27","kind":"exercise","planned":false,"acquired":true,"shares":972,"price":52.84,"value":51360.48,"ownership":{"direct":true},"balance_after":27679,"source":{"system":"sec-edgar","filing":"0002001011-26-000071","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000071/edgardoc.xml","form_type":"4"}},{"id":760779,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-28T23:43:04.000Z","date":"2026-05-27","kind":"exercise","planned":false,"acquired":true,"shares":764,"price":63.62,"value":48605.68,"ownership":{"direct":true},"balance_after":26707,"source":{"system":"sec-edgar","filing":"0002001011-26-000071","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000071/edgardoc.xml","form_type":"4"}},{"id":826815,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-03-28T01:20:27.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":23527,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter."}],"balance_after":23527,"derivative":{"exercise_price":202.55,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":23527},"source":{"system":"sec-edgar","filing":"0002001011-26-000035","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000035/primary_doc.xml","form_type":"4"}},{"id":826814,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-28T01:20:27.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":4933,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2027; February 15, 2028; and February 15, 2029, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Pursuant to an election under the Issuer's Nonqualified Deferred Compensation Plan, delivery of shares otherwise issuable upon each vesting date will be deferred."}],"balance_after":37945,"source":{"system":"sec-edgar","filing":"0002001011-26-000035","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000035/primary_doc.xml","form_type":"4"}},{"id":844784,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-03-13T23:29:34.000Z","date":"2026-03-11","kind":"exercise","planned":true,"acquired":false,"shares":2405,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":92.65,"expiration_date":"2028-03-02","underlying":"Common Stock","underlying_shares":2405},"source":{"system":"sec-edgar","filing":"0002001011-26-000026","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000026/edgardoc.xml","form_type":"4"}},{"id":844783,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-13T23:29:34.000Z","date":"2026-03-11","kind":"sale","planned":true,"acquired":false,"shares":3057,"price":225,"value":687825.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1."}],"balance_after":21010,"source":{"system":"sec-edgar","filing":"0002001011-26-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000026/edgardoc.xml","form_type":"4"}},{"id":844782,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-13T23:29:34.000Z","date":"2026-03-11","kind":"exercise","planned":true,"acquired":true,"shares":2405,"price":92.65,"value":222823.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1."}],"balance_after":24067,"source":{"system":"sec-edgar","filing":"0002001011-26-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000026/edgardoc.xml","form_type":"4"}},{"id":856983,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-03-06T23:49:54.000Z","date":"2026-03-04","kind":"exercise","planned":true,"acquired":false,"shares":466,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":80.72,"expiration_date":"2026-08-01","underlying":"Common Stock","underlying_shares":466},"source":{"system":"sec-edgar","filing":"0002001011-26-000023","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000023/edgardoc.xml","form_type":"4"}},{"id":856982,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-03-06T23:49:54.000Z","date":"2026-03-04","kind":"exercise","planned":true,"acquired":false,"shares":1607,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":58.49,"expiration_date":"2027-02-24","underlying":"Common Stock","underlying_shares":1607},"source":{"system":"sec-edgar","filing":"0002001011-26-000023","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000023/edgardoc.xml","form_type":"4"}},{"id":856981,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T23:49:54.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":3413,"price":208.796,"value":712620.748,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $208.3900 to $208.9500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":21662,"source":{"system":"sec-edgar","filing":"0002001011-26-000023","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000023/edgardoc.xml","form_type":"4"}},{"id":856980,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T23:49:54.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":2457,"price":207.9052,"value":510823.0764,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $207.4100 to $208.3500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":25075,"source":{"system":"sec-edgar","filing":"0002001011-26-000023","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000023/edgardoc.xml","form_type":"4"}},{"id":856979,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T23:49:54.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":1588,"price":206.8904,"value":328541.9552,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $206.4700 to $207.3500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":27532,"source":{"system":"sec-edgar","filing":"0002001011-26-000023","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000023/edgardoc.xml","form_type":"4"}},{"id":856978,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T23:49:54.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":1457,"price":205.7937,"value":299841.4209,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $205.3700 to $206.3600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":29120,"source":{"system":"sec-edgar","filing":"0002001011-26-000023","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000023/edgardoc.xml","form_type":"4"}},{"id":856977,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T23:49:54.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":743,"price":204.7449,"value":152125.4607,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $204.4600 to $205.3600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":30577,"source":{"system":"sec-edgar","filing":"0002001011-26-000023","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000023/edgardoc.xml","form_type":"4"}},{"id":856976,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T23:49:54.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":668,"price":203.6287,"value":136023.9716,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $203.4100 to $203.8600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":31320,"source":{"system":"sec-edgar","filing":"0002001011-26-000023","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000023/edgardoc.xml","form_type":"4"}},{"id":856975,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T23:49:54.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":697,"price":202.7873,"value":141342.7481,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $202.4000 to $203.0500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":31988,"source":{"system":"sec-edgar","filing":"0002001011-26-000023","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000023/edgardoc.xml","form_type":"4"}},{"id":856974,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T23:49:54.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":950,"price":201.7266,"value":191640.27,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $201.4600 to $202.3300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":32685,"source":{"system":"sec-edgar","filing":"0002001011-26-000023","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000023/edgardoc.xml","form_type":"4"}},{"id":856973,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T23:49:54.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":698,"price":201.0939,"value":140363.5422,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $200.5000 to $201.3400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":33635,"source":{"system":"sec-edgar","filing":"0002001011-26-000023","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000023/edgardoc.xml","form_type":"4"}},{"id":856972,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T23:49:54.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":53,"price":200.0777,"value":10604.1181,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $199.4400 to $200.0900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":34333,"source":{"system":"sec-edgar","filing":"0002001011-26-000023","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000023/edgardoc.xml","form_type":"4"}},{"id":856971,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T23:49:54.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":699,"price":198.7052,"value":138894.9348,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $198.3700 to $199.2500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":34386,"source":{"system":"sec-edgar","filing":"0002001011-26-000023","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000023/edgardoc.xml","form_type":"4"}},{"id":856970,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T23:49:54.000Z","date":"2026-03-04","kind":"exercise","planned":true,"acquired":true,"shares":466,"price":80.72,"value":37615.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1."}],"balance_after":35085,"source":{"system":"sec-edgar","filing":"0002001011-26-000023","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000023/edgardoc.xml","form_type":"4"}},{"id":856969,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T23:49:54.000Z","date":"2026-03-04","kind":"exercise","planned":true,"acquired":true,"shares":1607,"price":58.49,"value":93993.43,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 19, 2025, in accordance with Rule 10b5-1."}],"balance_after":34619,"source":{"system":"sec-edgar","filing":"0002001011-26-000023","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000023/edgardoc.xml","form_type":"4"}},{"id":898623,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:22:50.000Z","date":"2026-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":1270,"price":183.83,"value":233464.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":33012,"source":{"system":"sec-edgar","filing":"0002001011-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000012/edgardoc.xml","form_type":"4"}},{"id":898622,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:22:50.000Z","date":"2026-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":1223,"price":183.83,"value":224824.09,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":34282,"source":{"system":"sec-edgar","filing":"0002001011-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000012/edgardoc.xml","form_type":"4"}},{"id":898621,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:22:50.000Z","date":"2026-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":1026,"price":183.83,"value":188609.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":35505,"source":{"system":"sec-edgar","filing":"0002001011-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000012/edgardoc.xml","form_type":"4"}},{"id":898620,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:22:50.000Z","date":"2026-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":4483,"price":183.83,"value":824109.89,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of PSUs."}],"balance_after":36531,"source":{"system":"sec-edgar","filing":"0002001011-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000012/edgardoc.xml","form_type":"4"}},{"id":898619,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:22:50.000Z","date":"2026-02-14","kind":"grant","planned":false,"acquired":true,"shares":8810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock issued upon the vesting and certification of performance stock units (\"PSUs\")."}],"balance_after":41014,"source":{"system":"sec-edgar","filing":"0002001011-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000012/edgardoc.xml","form_type":"4"}},{"id":898618,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:22:50.000Z","date":"2026-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":3761,"price":183.83,"value":691384.63,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of PSUs."}],"balance_after":32204,"source":{"system":"sec-edgar","filing":"0002001011-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000012/edgardoc.xml","form_type":"4"}},{"id":898617,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:22:50.000Z","date":"2026-02-14","kind":"grant","planned":false,"acquired":true,"shares":7390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock issued upon the vesting and certification of performance stock units (\"PSUs\")."}],"balance_after":35965,"source":{"system":"sec-edgar","filing":"0002001011-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000012/edgardoc.xml","form_type":"4"}},{"id":948624,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-07T00:21:16.000Z","date":"2025-12-31","kind":"other","planned":false,"acquired":true,"shares":8,"price":95.676,"value":765.408,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":28575,"source":{"system":"sec-edgar","filing":"0002001011-26-000003","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000003/edgardoc.xml","form_type":"4"}},{"id":963693,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-18T21:19:42.000Z","date":"2025-12-16","kind":"exercise","planned":false,"acquired":false,"shares":181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests as to 50% of the underlying shares on January 3, 2025 and as to the remaining on February 3, 2025."}],"balance_after":4186,"derivative":{"exercise_price":103.42,"expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":181},"source":{"system":"sec-edgar","filing":"0002001011-25-000127","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000127/edgardoc.xml","form_type":"4"}},{"id":963692,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-18T21:19:42.000Z","date":"2025-12-16","kind":"exercise","planned":false,"acquired":false,"shares":652,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and exercisable."}],"balance_after":2405,"derivative":{"exercise_price":92.65,"expiration_date":"2028-03-02","underlying":"Common Stock","underlying_shares":652},"source":{"system":"sec-edgar","filing":"0002001011-25-000127","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000127/edgardoc.xml","form_type":"4"}},{"id":963691,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-18T21:19:42.000Z","date":"2025-12-16","kind":"exercise","planned":false,"acquired":false,"shares":285,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from December 5, 2022, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after December 5, 2022 and the remaining stock options vesting in 42 equal monthly installments thereafter."}],"balance_after":18171,"derivative":{"exercise_price":63.62,"expiration_date":"2032-12-13","underlying":"Common Stock","underlying_shares":285},"source":{"system":"sec-edgar","filing":"0002001011-25-000127","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000127/edgardoc.xml","form_type":"4"}},{"id":963690,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-18T21:19:42.000Z","date":"2025-12-16","kind":"exercise","planned":false,"acquired":false,"shares":69,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022."}],"balance_after":7171,"derivative":{"exercise_price":57.22,"expiration_date":"2030-10-01","underlying":"Common Stock","underlying_shares":69},"source":{"system":"sec-edgar","filing":"0002001011-25-000127","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000127/edgardoc.xml","form_type":"4"}},{"id":963689,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-18T21:19:42.000Z","date":"2025-12-16","kind":"exercise","planned":false,"acquired":false,"shares":1194,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to approximately 55% of the underlying shares in 12 substantially equal monthly installments beginning on January 5, 2025, and approximately 45% of the underlying shares in two substantially equal monthly installments thereafter."}],"balance_after":972,"derivative":{"exercise_price":52.84,"expiration_date":"2032-05-05","underlying":"Common Stock","underlying_shares":1194},"source":{"system":"sec-edgar","filing":"0002001011-25-000127","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000127/edgardoc.xml","form_type":"4"}},{"id":963688,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-18T21:19:42.000Z","date":"2025-12-16","kind":"exercise","planned":false,"acquired":true,"shares":181,"price":103.42,"value":18719.02,"ownership":{"direct":true},"balance_after":28567,"source":{"system":"sec-edgar","filing":"0002001011-25-000127","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000127/edgardoc.xml","form_type":"4"}},{"id":963687,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-18T21:19:42.000Z","date":"2025-12-16","kind":"exercise","planned":false,"acquired":true,"shares":652,"price":92.65,"value":60407.8,"ownership":{"direct":true},"balance_after":28386,"source":{"system":"sec-edgar","filing":"0002001011-25-000127","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000127/edgardoc.xml","form_type":"4"}},{"id":963686,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-18T21:19:42.000Z","date":"2025-12-16","kind":"exercise","planned":false,"acquired":true,"shares":285,"price":63.62,"value":18131.7,"ownership":{"direct":true},"balance_after":27734,"source":{"system":"sec-edgar","filing":"0002001011-25-000127","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000127/edgardoc.xml","form_type":"4"}},{"id":963685,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-18T21:19:42.000Z","date":"2025-12-16","kind":"exercise","planned":false,"acquired":true,"shares":69,"price":57.22,"value":3948.18,"ownership":{"direct":true},"balance_after":27449,"source":{"system":"sec-edgar","filing":"0002001011-25-000127","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000127/edgardoc.xml","form_type":"4"}},{"id":963684,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-18T21:19:42.000Z","date":"2025-12-16","kind":"exercise","planned":false,"acquired":true,"shares":1194,"price":52.84,"value":63090.96,"ownership":{"direct":true},"balance_after":27380,"source":{"system":"sec-edgar","filing":"0002001011-25-000127","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000127/edgardoc.xml","form_type":"4"}},{"id":968327,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-16T23:36:31.000Z","date":"2025-12-12","kind":"sale","planned":false,"acquired":false,"shares":1804,"price":188.31,"value":339711.24,"ownership":{"direct":true},"balance_after":26186,"source":{"system":"sec-edgar","filing":"0002001011-25-000125","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000125/edgardoc.xml","form_type":"4"}},{"id":976824,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-10T01:06:15.000Z","date":"2025-12-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":1862,"price":184.87,"value":344227.94,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":27990,"source":{"system":"sec-edgar","filing":"0002001011-25-000123","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000123/edgardoc.xml","form_type":"4"}},{"id":1096620,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-07-02T23:32:09.000Z","date":"2025-06-30","kind":"other","planned":false,"acquired":true,"shares":224,"price":91.0775,"value":20401.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":29852,"source":{"system":"sec-edgar","filing":"0002001011-25-000051","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000051/edgardoc.xml","form_type":"4"}},{"id":1151507,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-05-14T00:04:05.000Z","date":"2025-05-09","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":104.4,"value":52200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person's purchase of Ligand Pharmaceuticals Incorporated (\"Ligand\") common stock reported herein might be deemed matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,500 shares, with the reporting person's sale of 2,104 shares of Ligand common stock at the highest price of $116.71 per share on December 23, 2024. Accordingly, the reporting person has paid to Ligand, $18,975, representing the full amount of any profit realized if this were to be deemed to be a short-swing transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total includes 69 shares acquired on December 31, 2024, through the Issuer's Employee Stock Purchase Plan (ESPP)."}],"balance_after":27932,"source":{"system":"sec-edgar","filing":"0002001011-25-000028","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000028/edgardoc.xml","form_type":"4"}},{"id":1151506,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-05-14T00:04:05.000Z","date":"2025-05-09","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":103.89,"value":103890.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person's purchase of Ligand Pharmaceuticals Incorporated (\"Ligand\") common stock reported herein might be deemed matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,500 shares, with the reporting person's sale of 2,104 shares of Ligand common stock at the highest price of $116.71 per share on December 23, 2024. Accordingly, the reporting person has paid to Ligand, $18,975, representing the full amount of any profit realized if this were to be deemed to be a short-swing transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total includes 69 shares acquired on December 31, 2024, through the Issuer's Employee Stock Purchase Plan (ESPP)."}],"balance_after":27432,"source":{"system":"sec-edgar","filing":"0002001011-25-000028","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000028/edgardoc.xml","form_type":"4"}},{"id":1220652,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-06T23:55:23.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":32717,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter."}],"balance_after":32717,"derivative":{"exercise_price":115.26,"expiration_date":"2035-03-04","underlying":"Common Stock","underlying_shares":32717},"source":{"system":"sec-edgar","filing":"0002001011-25-000015","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000015/edgardoc.xml","form_type":"4"}},{"id":1220651,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-06T23:55:23.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":7484,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2026; February 15, 2027; and February 15, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":26363,"source":{"system":"sec-edgar","filing":"0002001011-25-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000015/edgardoc.xml","form_type":"4"}},{"id":1220650,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-06T23:55:23.000Z","date":"2025-03-04","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":115.0297,"value":575148.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.8900 to $115.1850, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":18879,"source":{"system":"sec-edgar","filing":"0002001011-25-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000015/edgardoc.xml","form_type":"4"}},{"id":1261990,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-20T01:38:58.000Z","date":"2025-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":1221,"price":120,"value":146520.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":23879,"source":{"system":"sec-edgar","filing":"0002001011-25-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000011/edgardoc.xml","form_type":"4"}},{"id":1261989,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-20T01:38:58.000Z","date":"2025-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":782,"price":120,"value":93840.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":25100,"source":{"system":"sec-edgar","filing":"0002001011-25-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000011/edgardoc.xml","form_type":"4"}},{"id":1261988,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-20T01:38:58.000Z","date":"2025-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":1024,"price":120,"value":122880.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":25882,"source":{"system":"sec-edgar","filing":"0002001011-25-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000011/edgardoc.xml","form_type":"4"}},{"id":1261987,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-20T01:38:58.000Z","date":"2025-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":3803,"price":120,"value":456360.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of performance stock units."}],"balance_after":26906,"source":{"system":"sec-edgar","filing":"0002001011-25-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000011/edgardoc.xml","form_type":"4"}},{"id":1261986,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-20T01:38:58.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":7390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock issued upon the vesting and certification of performance stock units (PSUs)."}],"balance_after":30709,"source":{"system":"sec-edgar","filing":"0002001011-25-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000011/edgardoc.xml","form_type":"4"}},{"id":1261985,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-20T01:38:58.000Z","date":"2025-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":2757,"price":120,"value":330840.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of performance stock units."}],"balance_after":23319,"source":{"system":"sec-edgar","filing":"0002001011-25-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000011/edgardoc.xml","form_type":"4"}},{"id":1261984,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-20T01:38:58.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":5429,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock issued upon the vesting and certification of performance stock units (PSUs)."}],"balance_after":26076,"source":{"system":"sec-edgar","filing":"0002001011-25-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000011/edgardoc.xml","form_type":"4"}},{"id":1322290,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-27T01:32:43.000Z","date":"2024-12-23","kind":"sale","planned":false,"acquired":false,"shares":2104,"price":116.3738,"value":244850.4752,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.33 to $116.71, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":20647,"source":{"system":"sec-edgar","filing":"0002001011-24-000107","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000107/edgardoc.xml","form_type":"4"}},{"id":1340997,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-07T00:55:21.000Z","date":"2024-12-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":1859,"price":123.51,"value":229605.09,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":22751,"source":{"system":"sec-edgar","filing":"0002001011-24-000100","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000100/edgardoc.xml","form_type":"4"}},{"id":1400576,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-24T23:41:37.000Z","date":"2024-09-20","kind":"sale","planned":false,"acquired":false,"shares":800,"price":103.95,"value":83160.0,"ownership":{"direct":true},"balance_after":24610,"source":{"system":"sec-edgar","filing":"0002001011-24-000088","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000088/edgardoc.xml","form_type":"4"}},{"id":1400575,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-24T23:41:37.000Z","date":"2024-09-20","kind":"sale","planned":false,"acquired":false,"shares":275,"price":103.8625,"value":28562.1875,"ownership":{"direct":true},"balance_after":25410,"source":{"system":"sec-edgar","filing":"0002001011-24-000088","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000088/edgardoc.xml","form_type":"4"}},{"id":1400574,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-24T23:41:37.000Z","date":"2024-09-20","kind":"sale","planned":false,"acquired":false,"shares":200,"price":103.98,"value":20796.0,"ownership":{"direct":true},"balance_after":25685,"source":{"system":"sec-edgar","filing":"0002001011-24-000088","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000088/edgardoc.xml","form_type":"4"}},{"id":1402826,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-09-19T21:50:09.000Z","date":"2024-09-17","kind":"exercise","planned":false,"acquired":false,"shares":1417,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":466,"derivative":{"exercise_price":80.72,"expiration_date":"2026-08-01","underlying":"Common Stock","underlying_shares":1417},"source":{"system":"sec-edgar","filing":"0002001011-24-000084","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000084/edgardoc.xml","form_type":"4"}},{"id":1402825,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-09-19T21:50:09.000Z","date":"2024-09-17","kind":"exercise","planned":false,"acquired":false,"shares":69,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022."}],"balance_after":7240,"derivative":{"exercise_price":57.22,"expiration_date":"2030-10-01","underlying":"Common Stock","underlying_shares":69},"source":{"system":"sec-edgar","filing":"0002001011-24-000084","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000084/edgardoc.xml","form_type":"4"}},{"id":1402824,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-19T21:50:09.000Z","date":"2024-09-17","kind":"exercise","planned":false,"acquired":true,"shares":69,"price":57.22,"value":3948.18,"ownership":{"direct":true},"balance_after":25885,"source":{"system":"sec-edgar","filing":"0002001011-24-000084","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000084/edgardoc.xml","form_type":"4"}},{"id":1402823,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-19T21:50:09.000Z","date":"2024-09-17","kind":"exercise","planned":false,"acquired":true,"shares":1417,"price":80.72,"value":114380.24,"ownership":{"direct":true},"balance_after":25816,"source":{"system":"sec-edgar","filing":"0002001011-24-000084","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000084/edgardoc.xml","form_type":"4"}},{"id":1419388,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2024-08-31T01:00:59.000Z","date":"2024-08-28","kind":"exercise","planned":false,"acquired":false,"shares":546,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As per the separation of OmniAb Inc. from the issuer, 402 stock options were vested and exercisable as of November 1, 2022, whereas 144 options vest in 3 substantially equal monthly installments beginning on December 1, 2022."}],"balance_after":0,"derivative":{"exercise_price":70.04,"expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":546},"source":{"system":"sec-edgar","filing":"0002001011-24-000080","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000080/edgardoc.xml","form_type":"4"}},{"id":1419387,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-08-31T01:00:59.000Z","date":"2024-08-28","kind":"exercise","planned":false,"acquired":false,"shares":207,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and is exercisable as to approximately 14% of the underlying shares on April 1, 2021, approximately 73% of the underlying shares in 32 substantially equal monthly installments on May 5, 2021, and approximately 13% of the underlying shares in 10 substantially equal monthly installments thereafter."}],"balance_after":7309,"derivative":{"exercise_price":57.22,"expiration_date":"2030-10-01","underlying":"Common Stock","underlying_shares":207},"source":{"system":"sec-edgar","filing":"0002001011-24-000080","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000080/edgardoc.xml","form_type":"4"}},{"id":1419386,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-08-31T01:00:59.000Z","date":"2024-08-28","kind":"exercise","planned":false,"acquired":true,"shares":546,"price":70.04,"value":38241.84,"ownership":{"direct":true},"balance_after":24399,"source":{"system":"sec-edgar","filing":"0002001011-24-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000080/edgardoc.xml","form_type":"4"}},{"id":1419385,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-08-31T01:00:59.000Z","date":"2024-08-28","kind":"exercise","planned":false,"acquired":true,"shares":207,"price":57.22,"value":11844.54,"ownership":{"direct":true},"balance_after":23853,"source":{"system":"sec-edgar","filing":"0002001011-24-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000080/edgardoc.xml","form_type":"4"}},{"id":1464307,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-07-02T23:45:13.000Z","date":"2024-06-28","kind":"other","planned":false,"acquired":true,"shares":267,"price":60.707,"value":16208.769,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":23646,"source":{"system":"sec-edgar","filing":"0002001011-24-000063","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000063/edgardoc.xml","form_type":"4"}},{"id":1512763,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-05-17T23:59:50.000Z","date":"2024-05-17","kind":"exercise","planned":false,"acquired":false,"shares":5022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests and is exercisable as to approximately 14% of the underlying shares on August 5, 2022, approximately 64% of the underlying shares in 28 substantially equal monthly installments beginning on September 5, 2022, and approximately 22% of the underlying shares in 12 substantially equal monthly installments thereafter."}],"balance_after":16179,"derivative":{"exercise_price":52.84,"expiration_date":"2032-05-05","underlying":"Common Stock","underlying_shares":5022},"source":{"system":"sec-edgar","filing":"0002001011-24-000053","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000053/edgardoc.xml","form_type":"4"}},{"id":1512762,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2024-05-17T23:59:50.000Z","date":"2024-05-17","kind":"exercise","planned":false,"acquired":false,"shares":145,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests as to 50% of the underlying shares on January 11, 2023 and as to the remaining on February 11, 2023."}],"balance_after":0,"derivative":{"exercise_price":68.74,"expiration_date":"2029-02-11","underlying":"Common Stock","underlying_shares":145},"source":{"system":"sec-edgar","filing":"0002001011-24-000053","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000053/edgardoc.xml","form_type":"4"}},{"id":1512761,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-05-17T23:59:50.000Z","date":"2024-05-17","kind":"exercise","planned":false,"acquired":false,"shares":1544,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from December 5, 2022, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after December 5, 2022 and the remaining stock options vesting in 42 equal monthly installments thereafter."}],"balance_after":18456,"derivative":{"exercise_price":63.62,"expiration_date":"2032-12-13","underlying":"Common Stock","underlying_shares":1544},"source":{"system":"sec-edgar","filing":"0002001011-24-000053","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000053/edgardoc.xml","form_type":"4"}},{"id":1512760,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-05-17T23:59:50.000Z","date":"2024-05-17","kind":"exercise","planned":false,"acquired":false,"shares":206,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022."}],"balance_after":7516,"derivative":{"exercise_price":57.22,"expiration_date":"2030-10-01","underlying":"Common Stock","underlying_shares":206},"source":{"system":"sec-edgar","filing":"0002001011-24-000053","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000053/edgardoc.xml","form_type":"4"}},{"id":1512759,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-17T23:59:50.000Z","date":"2024-05-17","kind":"sale","planned":false,"acquired":false,"shares":134,"price":86.6497,"value":11611.0598,"ownership":{"direct":true},"balance_after":23379,"source":{"system":"sec-edgar","filing":"0002001011-24-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000053/edgardoc.xml","form_type":"4"}},{"id":1512758,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-17T23:59:50.000Z","date":"2024-05-17","kind":"sale","planned":false,"acquired":false,"shares":5022,"price":86.6652,"value":435232.6344,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0300 to $86.8200. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":23513,"source":{"system":"sec-edgar","filing":"0002001011-24-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000053/edgardoc.xml","form_type":"4"}},{"id":1512757,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-17T23:59:50.000Z","date":"2024-05-17","kind":"exercise","planned":false,"acquired":true,"shares":5022,"price":52.84,"value":265362.48,"ownership":{"direct":true},"balance_after":28535,"source":{"system":"sec-edgar","filing":"0002001011-24-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000053/edgardoc.xml","form_type":"4"}},{"id":1512756,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-17T23:59:50.000Z","date":"2024-05-17","kind":"exercise","planned":false,"acquired":true,"shares":145,"price":68.74,"value":9967.3,"ownership":{"direct":true},"balance_after":23513,"source":{"system":"sec-edgar","filing":"0002001011-24-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000053/edgardoc.xml","form_type":"4"}},{"id":1512755,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-17T23:59:50.000Z","date":"2024-05-17","kind":"exercise","planned":false,"acquired":true,"shares":1544,"price":63.62,"value":98229.28,"ownership":{"direct":true},"balance_after":23368,"source":{"system":"sec-edgar","filing":"0002001011-24-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000053/edgardoc.xml","form_type":"4"}},{"id":1512754,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-17T23:59:50.000Z","date":"2024-05-17","kind":"exercise","planned":false,"acquired":true,"shares":206,"price":57.22,"value":11787.32,"ownership":{"direct":true},"balance_after":21824,"source":{"system":"sec-edgar","filing":"0002001011-24-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000053/edgardoc.xml","form_type":"4"}},{"id":1512753,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-17T23:59:50.000Z","date":"2024-05-16","kind":"sale","planned":false,"acquired":false,"shares":2264,"price":86.0034,"value":194711.6976,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0000 to $86.0350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":21618,"source":{"system":"sec-edgar","filing":"0002001011-24-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000053/edgardoc.xml","form_type":"4"}},{"id":1512752,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-17T23:59:50.000Z","date":"2024-05-15","kind":"sale","planned":false,"acquired":false,"shares":5873,"price":86.012,"value":505148.476,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0000 to $86.1500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":23882,"source":{"system":"sec-edgar","filing":"0002001011-24-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000053/edgardoc.xml","form_type":"4"}},{"id":1611038,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-29T23:50:28.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":29272,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter."}],"balance_after":29272,"derivative":{"exercise_price":89.2,"expiration_date":"2034-02-27","underlying":"Common Stock","underlying_shares":29272},"source":{"system":"sec-edgar","filing":"0002001011-24-000028","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000028/edgardoc.xml","form_type":"4"}},{"id":1611037,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-29T23:50:28.000Z","date":"2024-02-28","kind":"exercise","planned":false,"acquired":false,"shares":325,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and exercisable."}],"balance_after":1607,"derivative":{"exercise_price":58.49,"expiration_date":"2027-02-24","underlying":"Common Stock","underlying_shares":325},"source":{"system":"sec-edgar","filing":"0002001011-24-000028","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000028/edgardoc.xml","form_type":"4"}},{"id":1611036,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-29T23:50:28.000Z","date":"2024-02-28","kind":"exercise","planned":false,"acquired":false,"shares":140,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022."}],"balance_after":7722,"derivative":{"exercise_price":57.22,"expiration_date":"2030-10-01","underlying":"Common Stock","underlying_shares":140},"source":{"system":"sec-edgar","filing":"0002001011-24-000028","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000028/edgardoc.xml","form_type":"4"}},{"id":1611035,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-29T23:50:28.000Z","date":"2024-02-28","kind":"exercise","planned":false,"acquired":false,"shares":799,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As per the separation of OmniAb Inc. from the issuer, 2,039 stock options were vested and exercisable as of November 1, 2022, whereas 1,629 options vest in 16 substantially equal monthly installments beginning on November 13, 2022."}],"balance_after":2869,"derivative":{"exercise_price":55.75,"expiration_date":"2030-02-13","underlying":"Common Stock","underlying_shares":799},"source":{"system":"sec-edgar","filing":"0002001011-24-000028","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000028/edgardoc.xml","form_type":"4"}},{"id":1611034,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-29T23:50:28.000Z","date":"2024-02-28","kind":"sale","planned":false,"acquired":false,"shares":140,"price":88.46,"value":12384.4,"ownership":{"direct":true},"balance_after":29755,"source":{"system":"sec-edgar","filing":"0002001011-24-000028","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000028/edgardoc.xml","form_type":"4"}}],"next_cursor":"2024-02-29T23:50:28.000000Z,1611034"}